20:51 , Jul 12, 2018 |  BC Extra  |  Preclinical News

Virus-free CRISPR T cell editing

A team led by University of California San Francisco researchers developed a non-viral method to engineer T cell genomes in about one week using CRISPR/Cas9 DNA editing. The method could reduce the time and cost...
18:11 , Jun 29, 2018 |  BC Week In Review  |  Financial News

Autolus raises $150M in upsized IPO

Autolus Therapeutics plc (NASDAQ:AUTL) climbed $8 (47%) to $25 its first day of trading on June 22 after it raised $150 million via the sale of 8.8 million ADSs at $17 in an upsized IPO....
14:57 , Jun 29, 2018 |  BC Week In Review  |  Company News

AbbVie, Calibr to develop universal CAR T therapies

AbbVie Inc. (NYSE:ABBV) and the California Institute for Biomedical Research (La Jolla, Calif.) partnered to develop universal CAR T therapies using the non-profit's switchable CAR T technology to treat hematological and solid tumors. AbbVie will pay...
00:43 , Jun 29, 2018 |  BC Innovations  |  Product R&D

Highly personal

Pact Pharma Inc. has raised $120 million in venture financing to tackle one of the most complex forms of personalized medicine proposed to date: neoantigen-targeted T cells. Backed by Alphabet Inc.’s GV, the company is...
18:25 , Jun 28, 2018 |  BC Innovations  |  Translation in Brief

Synchronous signaling

As researchers explore next-generation CARs in cancer, one strategy is to tinker with the receptors’ modular components. A Science Signaling paper suggests that altering the number of ITAM repeats in the intracellular domains of a...
17:46 , Jun 28, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Cell therapy CAR T cells with six ITAMS could have greater activity towards cancer cells than CAR T cells with the standard three ITAMS. The cells are generated by duplicating the CD3ζ (CD3z; CD247)...
11:26 , Jun 25, 2018 |  BC Extra  |  Company News

AbbVie, Calibr to develop universal CAR T therapies

AbbVie Inc. (NYSE:ABBV) and the California Institute for Biomedical Research (La Jolla, Calif.) partnered to develop universal CAR T therapies using the non-profit's switchable CAR T technology to treat hematological and solid tumors. AbbVie will pay...
18:36 , Jun 22, 2018 |  BC Week In Review  |  Financial News

Qiming leads series B for cancer play WindMIL

WindMIL Therapeutics Inc. (Baltimore, Md.) raised $32.5 million on June 18 in an untranched series B round led by Qiming Venture Partners. Fellow new investors Medivate Partners, Camden Partners Nexus and the Kinneret Group participated...
17:58 , Jun 22, 2018 |  BC Week In Review  |  Clinical News

FDA places hold on upcoming Phase I for point-of-care CAR Ts

FDA placed a clinical hold on an upcoming Phase I trial sponsored by Ziopharm Oncology Inc. (NASDAQ:ZIOP), which would be the first for its third-generation, point-of-care CAR T cells that require two days for manufacturing....
02:56 , Jun 22, 2018 |  BC Extra  |  Financial News

First-day bump for Autolus after pricing $150M IPO

Autolus Therapeutics plc (NASDAQ:AUTL) climbed $8 (47%) to $25 its first day of trading Friday after it raised $150 million via the sale of 8.8 million ADSs at $17 in an upsized IPO. Underwriters are...